| Field | Specification |
|---|---|
| Target | |
| Alternative names | Signal transducer and activator of transcription 1-alpha/beta;Transcription factor ISGF-3 components p91/p84;STAT1; |
| UniProt # | |
| Host | |
| Clonality | |
| Isotype | |
| Reactivity | |
| Applications | |
| Immunogen | E.coli-derived human STAT1 recombinant protein (Position: S2-A230). Human STAT1 shares 91.2% amino acid (aa) sequence identity with mouse STAT1. |
| Molecular weight | |
| Purification | |
| Reconstitution | |
| Cellular localization | |
| Concentration | |
| Form | Lyophilized |
| Storage | |
| Catalog no. (Mfr.) | |
| Main SKU |
Product Overview
This rabbit polyclonal antibody detects signal transducer and activator of transcription 1-alpha/beta (gene STAT1) in human samples and is validated for flow cytometry, ICC/IF, IHC and Western blot. The predicted molecular weight is 87.3 kDa, and the supplier reports an observed band at about 91 kDa.
STAT1 is a transcription factor activated by JAK kinases downstream of interferon receptors. After type I interferon signaling it joins STAT2 and IRF9 in the ISGF3 complex, while IFN-γ induces STAT1 homodimers; both drive interferon-stimulated genes. STAT1 is therefore central to antiviral defense, macrophage activation and immune regulation studies.
| Target | Signal transducer and activator of transcription 1-alpha/beta (gene STAT1; UniProt P42224, human) |
|---|---|
| Host / Clonality / Isotype | Rabbit / Polyclonal / Rabbit IgG |
| Reactivity | Human |
| Form | Lyophilized |
| Formulation | Per vial: 4 mg trehalose; 0.9 mg NaCl; 0.2 mg Na2HPO4; 0.05 mg NaN3 |
| Calculated MW | 87.3 kDa |
| Observed MW | 91 kDa |
| Storage | As supplied: −20 °C for up to 12 months from receipt. After reconstitution: 4 °C for up to 1 month, or aliquot and keep at −20 °C for up to 6 months. Avoid repeated freeze–thaw cycles. |
Validated Applications
| Western blot | 0.1–0.5 µg/mL |
|---|---|
| IHC (paraffin sections) | 0.5–1 µg/mL |
| Immunocytochemistry / Immunofluorescence | 2 µg/mL |
| Flow cytometry (fixed cells) | 1–3 µg/1×106 cells |
Samples with a confirmed band (WB): human HeLa cells, human PC-3 cells, human Caco-2 cells, human Raji cells.
Recommended loading (WB): 20–40 µg of total protein per lane.
Conditions in the example images (WB): 5–20% gradient SDS-PAGE under reducing conditions, 30 µg lysate per lane, transfer to nitrocellulose membrane, blocking in 5% non-fat milk, primary antibody at 0.5 µg/mL overnight at 4 °C, HRP-conjugated secondary antibody at 1:5000, ECL detection.
Samples with confirmed staining (IHC): human intestinal cancer tissue.
Recommended antigen retrieval: heat-mediated, in TE buffer (pH 9.0); citrate buffer (pH 6.0) can be used instead.
Conditions in the example images (IHC): heat-mediated antigen retrieval in citrate buffer (pH 6).
Samples with confirmed staining (ICC/IF): U2OS cells.
Samples with a confirmed signal (flow cytometry): A431 cells.
Immunogen
Recombinant human STAT1 fragment (Ser2–Ala230), expressed in E. coli. Sequence identity with the mouse ortholog: 91.2%.
Reactivity Notes
The supplier lists reactivity with human. UniProt places signal transducer and activator of transcription 1-alpha/beta in the cytoplasm and nucleus. The samples tested by the supplier (listed above) are a practical starting point for positive controls.
Safety
Customization & Add-ons: Can’t find the antibody you need—or require a custom format for your assay? We can help you source the best match or support custom antibody solutions for diverse research needs, including species and isotype selection, conjugations and labeling (e.g., HRP/AP, biotin, fluorophores), purification grade options (Protein A/G, affinity purified), formulation preferences (buffer selection, carrier-free, glycerol-free), custom concentrations and aliquoting, low-endotoxin options for cell-based work, and application-focused QC/validation support (project dependent). Click Talk to a Scientist to submit a request, email us at support@biohippo.com, or explore our Research Services for additional support—our team will follow up with feasibility details and next steps.
